Introduction: Sphingolipids are associated with the regulation of pulmonary
Despite advances in medicine over the past decades, CF remains a debilitating, life-shortening disease. While many organ systems are affected by CF, the most common cause of patient morbidity and mortality is lung disease, which is characterized by recurring cycles of infection and neutrophilic inflammation. 1 Patients' airways contain high concentrations of proteolytic enzymes, such as neutrophil elastase (NE), a biomarker for lung disease progression in CF. Patients with CF can have up to micromolar concentrations of NE in their airways, and this protease further stimulates an inflammatory response. 2 The cycle of infection and over-exuberant inflammation damages the lungs, resulting in gradual decrements in lung function and eventually resulting in respiratory failure.
Bioactive lipids, such as sphingolipids, can act as signaling molecules; the sphingolipids ceramide, ceramide-1-phosphate, and sphingosine-1-phosphate in particular have been implicated as modulators of pulmonary inflammation, with ceramide and ceramide-1-phosphate being regarded as pro-inflammatory. [3] [4] [5] [6] Studies of sphingolipid imbalances in CF have focused on changes that result from CF transmembrane conductance regulator (CFTR) dysfunction. We have previously demonstrated, using a mouse model of NE-induced inflammation, [10] [11] [12] that NE increases the concentration of ceramide in murine airways, due to increases in d 18 13 This increase in ceramide is associated with a concurrent increase in serine palmitoyltransferase (SPT) long chain 2, a subunit of the enzyme that catalyzes a rate-limiting step in de novo sphingolipid synthesis, and upregulation of d 18:1/22:0 and d 18:1/24:1 ceramide can be blocked using an SPT inhibitor, such as myriocin. 13 Administering myriocin to NE-treated animals also decreases pro-inflammatory signals, including CXCL1/keratinocyte chemoattractant (KC, the mouse homologue of IL8) and high mobility group box 1 (HMGB1), though it does not affect the total white blood cell count or percent of neutrophils present in murine bronchoalveolar lavage. 13 There are few studies describing the sphingolipid content present in bronchoalveolar lavage or sputum from patients with CF. Analysis of CF sputum identified elevated sphingomyelin and ceramide compared to control samples gathered from healthy donors, with no apparent correlation to the presence of any bacterial genera. 14, 15 In a longitudinal study of one individual with CF, during four pulmonary exacerbations, sputum ceramide (d 18:1/16:0 ) was significantly increased, suggesting an association between sputum ceramide levels and airway inflammation. 15 To the extent of our knowledge, there are currently no studies that evaluate whether human NE or other inflammatory mediators correlate with ceramide levels in sputum. We hypothesized that an increased level of ceramide in sputum from patients with CF would correlate with increasing concentrations of active NE. were gathered between 1 and 9 days of admission with CF pulmonary exacerbation, with the median day of sampling being day 1. Sputa collected on the day patients were advised to be admitted were also labeled as day 1 of hospitalization. An aliquot of sputum was sent for bacteriology cultures, performed according to CFF standard protocols at the beginning of therapy. 16 The remaining aliquots of sputum were visually separated from saliva and oral detritus, and stored for later analysis at −80°C.
| Subject demographics
Mean subject age was 20 years, median subject age was 18 years, and the age range was 12-39 years of age. Eleven out of 15 patients were followed in Pediatric CF Center because they were less than 21 years of age. 
| Statistical analyses
We used a two-tailed, nonparametric, paired statistical test: the Wilcoxon signed rank test, to determine whether there were significant differences between stable and exacerbated sputum measures for sphingolipid levels, the concentration of active NE, and FEV 1 % predicted using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA). 23 Differences between groups were considered significant at P < 0.05.
We used linear correlation to assess the association between concentration of active NE and sphingolipid levels using GraphPad Prism 5 (GraphPad Software, Inc.). Data were analyzed using a linear mixed model, 24 to determine the likelihood of an association between the concentration of NE and various sphingolipids, as well as whether (i) bacterial culture positive for methicillin resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa;
(ii) patient lung function; or (iii) patient gender, modified the association. A P-value less than 0.05 was considered statistically significant. 
| Modifying factors that influence the association between sphingolipids and NE in CF sputum
The presence of bacteria in sputum, severity of lung disease, and patient gender modified the association between active NE and certain sphingolipid moieties in CF sputum. Sputa that were positive for MRSA had significantly strengthened associations with Sputa from females had a stronger association between those two sphingolipid moieties and active NE (Table 1) .
| DISCUSSION
In this study, we report a novel observation, demonstrating a relationship between active NE and sphingolipids present in the sputum of patients with CF. Increasing concentrations of NE were associated with higher levels of a variety of sphingolipids in sputum;
there were statistically significant linear correlations between the levels of active NE and the concentrations of total sphingomyelin, ceramide, monohexosylceramide, and S1P.
While our focus has been inflammation, heretofore, the aberrant sphingolipid homeostasis observed in airway and nasal culture of human Cftr-deficient cells 8, 25, 26 and Cftr-deficient mice, There are several mouse models with different Cftr mutations which display varying levels of CFTR function, 27 and, much like experiments with FIGURE 1 Differences in lung function and sputum concentrations of active NE and sphingolipids in patients with CF. Sputum samples were collected during the course of hospitalization or during an outpatient visit (n = 15 per group), and processed as described in Section 2. Lung function, expressed as FEV1 % predicted, varied between the two groups; there was a statistically significant decrease in lung function during hospitalization for CF pulmonary exacerbation (A). Active NE was measured by a chromogenic microtiter plate assay; there was a wide range of NE activity among patients, but no statistically significant difference between the two sample groups (B). Sphingolipid content was measured by HPLC-ESI-MS/MS. Sputum concentrations of d 18:1/14:0 ceramide (C), d 18:1/24:1 ceramide (D), and d18:1/24:0 monohexosylceramide (E) varied with clinical status, with increased concentrations of these sphingolipids found in samples collected during hospitalization. The differences between the two groups were statistically significant (*, P < 0.05). Data (mean ± SEM) were compared by Wilcoxon signed rank tests human airway epithelial cell lines, disparate results regarding changes in ceramide levels. One variable is whether gut Cftr-deficiency in CFTR-null mice is corrected by replacement with FABP-driven (intestinal fatty acid binding protein-driven) human CFTR. The impact of gut correction is that these mice do not require a special cholesterol rich diet and the change in diet affects sphingolipid homeostasis. 8 Nevertheless, while studies in Cftrdeficient mouse models report both increased 29 and decreased 30 ceramide in mouse airways, normalizing pulmonary ceramide levels decreases pro-inflammatory signals. 29, 30 Inflammation, oxidative stress, and sphingolipid biosynthesis are interconnected; many inflammatory mediators can alter sphingolipid levels by regulating enzymes involved in ceramide generation. For example, oxidative stress and inflammatory cytokines activate acid SMase. 31 Exposure to cigarette smoke elevates airway neutral SMase, increasing ceramide generation in mice. 32 Likewise, cigarette smoke increases neutral SMase in epithelial and endothelial cells, resulting in increased ceramide and subsequent apoptosis in these cell types. 32 Notably, increased neutral SMase has been observed in lung tissue from smokers with emphysema 32 ; however, cigarette smoke exposure is also known to lead to CFTR dysfunction in the lungs, 33 which may impact ceramide homeostasis as discussed above. The relationship between sphingolipid production and oxidative stress is complex. While reactive oxygen species have been reported to affect sphingolipid homeostasis by affecting both enzymatic activity and cellular levels of enzymes involved in sphingolipid production, published data also indicate that ceramide, sphingosine, and sphingosine-1-phosphate can modulate cellular redox. For example, ceramide activates NADPH oxidase, xanthine oxidase, and enzymes in the mitochondrial respiratory chain. 34 Excess ceramide induces oxidative stress and increases apoptosis of airway cells. 35 Furthermore, increased ceramide induces epithelial and endothelial permeability, promotes susceptibility to P. aeruginosa infection, 31 and activates the inflammasome, 36 likely contributing to oxidative stress, inflammation, and altered sphingolipid homeostasis in the CF airway. 3 Recently, using a mouse model of intratracheal NE-induced inflammation, [10] [11] [12] we demonstrated that active NE regulates sphingolipid expression. 13 In this model, oropharyngeal aspiration of exogenous NE increases total ceramide specifically Limited data are available regarding the sphingolipid content in the lung tissue and sputum of patients with CF. Decreased sphingosine and increased ceramide are evident in the nasal epithelium in CF, 26 with the latter also noted in lower airways of patients. 9 Brodlie et al described Methicillin-resistant S. aureus and P. aeruginosa are two of the most common bacterial pathogens that chronically infect CF airways;
thus, we examined whether the presence of these bacteria in sputum moieties, and overall demonstrated a trend towards higher levels of dihydroceramides. The significance of these sex-related influences on sphingolipid and NE associations remains to be determined.
While our analysis of CF sputum implies a relationship between active NE and sphingolipid biosynthesis, our study has several limitations. First, the number of samples assessed in this study were few, with only 15 subjects participating in the study. All of the sputum samples in the VCU Biospecimen Repository were spontaneously expectorated, which limits sample availability; not all patients with CF spontaneously expectorate sputum. Additionally, most of the subjects had severe (FEV 1 < 50% predicted) obstructive lung disease, which was reflected by the low, but still statistically significant, difference in FEV 1 % predicted when patients were hospitalized for CF pulmonary exacerbation versus outpatient, as well as the lack of significant difference in active NE observed in sputum between those two sample groups.
The sphingolipids detected in CF sputum could be present due to shedding of sphingolipid-rich extracellular vesicles (eg, microvesicles, exosomes, ectosomes). If so, the cellular source or sources remain unknown. 
